Edition:
United Kingdom

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

28.98USD
21 Sep 2018
Change (% chg)

$-0.17 (-0.58%)
Prev Close
$29.15
Open
$29.27
Day's High
$29.40
Day's Low
$28.65
Volume
76,568
Avg. Vol
43,662
52-wk High
$38.85
52-wk Low
$22.65

Chart for

About

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid... (more)

Overall

Beta: --
Market Cap(Mil.): $1,013.89
Shares Outstanding(Mil.): 35.42
Dividend: --
Yield (%): --

Financials

  CLLS.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.24 -- --
ROI: -27.62 1.79 14.61
ROE: -27.69 3.28 16.33

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO

02 Aug 2018

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

13 Jun 2018

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

23 May 2018

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

03 May 2018

BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome

* SAID ON TUESDAY THAT HARVARD’S WYSS INSTITUTE PARTNERS WITH CELLECTIS TO RECODE HUMAN GENOME

02 May 2018

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

04 Apr 2018

Pfizer in deal with Allogene to develop cancer cell therapies

Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients.

03 Apr 2018

UPDATE 1-Pfizer in deal with Allogene to develop cancer cell therapies

April 3 Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients.

03 Apr 2018

Pfizer signs deal with Allogene to develop cancer cell therapy

April 3 Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.

03 Apr 2018

Earnings vs. Estimates